Nighat Mehdi

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials”.

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(22)00504-5

N/A

1.5DataRank · unranked

67 citations

Gordon MacGregor, Pilar Azevedo, V. Indihar, Claire Keating, Marcus Mall +77 more

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor

Annals of the American Thoracic Society(2025)10.1513/annalsats.202507-817oc

N/A

0.396DataRank · unranked

8 citations

T. Spencer Poore, Brandie D. Wagner, Jing Xie, Sonya L. Heltshe, Mary Cross +65 more